-
Product Name
Anti-SFTPD / SP-D / SFTP4 antibody
- Documents
-
Description
Rabbit monoclonal to SFTPD / SP-D / SFTP4
-
Tested applications
IHC-P
-
Species reactivity
Rhesus SFTPD / SP-D / SFTP4
No cross-reactivity in ELISA with Human SFTPD -
Alternative names
AI573415 antibody; COLEC7 antibody; PSP-D antibody; Sftp4 antibody; SFTP4 antibody; SFTPD antibody; SFTPD antibody; SP-D antibody; SP-D antibody; SP-D antibody; PSP-D antibody; SFTP4 antibody; COLEC7 antibody; SP-D antibody; Sftp4 antibody; AI573415 antibody
- Immunogen
-
Isotype
Rabbit IgG
-
Preparation
This antibody was obtained from a rabbit immunized with purified, recombinant Rhesus SFTPD / SP-D / SFTP4 (NP_001035283.1; Met1-Phe375).
-
Clonality
Monoclonal
-
Formulation
0.2 μm filtered solution in PBS
-
Storage instructions
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. -
Applications
IHC-P: 1-10 μg/mL
-
Validations
SFTPD / SP-D / SFTP4 Antibody, Rabbit MAb, Immunohistochemistry
Immunochemical staining of cynomolgus SFTPD in cynomolgus lung with rabbit monoclonal antibody (5 µg/mL, formalin-fixed paraffin embedded sections).
-
Background
Surfactant pulmonary-associated protein D, also known as SFTPD and SP-D, is a member of the collectin family of C-type lectins that is synthesized in many tissues including respiratory epithelial cells in the lung, and contains one C-type lectin domain and one collagen-like domain. The polymorphic variation in the N-terminal domain of the SP-D molecule influences oligomerization, function, and the concentration of the molecule in serum. SFTPD is produced primarily by alveolar type II cells and nonciliated bronchiolar cells in the lung and is constitutively secreted into the alveoli where it influences surfactant homeostasis, effector cell functions, and host defense. It is upregulated in a variety of inflammatory and infectious conditions including Pneumocystis pneumonia and asthma. SFTPD is humoral molecules of the innate immune system, and is considered a functional candidate in chronic periodontitis. Besides it is involved in the development of acute and chronic inflammation of the lung. Several human lung diseases are characterized by decreased levels of bronchoalveolar SFTPD. Thus, recombinant SFTPD has been proposed as a therapeutical option for cystic fibrosis, neonatal lung disease and smoking-induced emphysema. Furthermore, SFTPD serum levels can be used as disease activity markers for interstitial lung diseases.
-
References
- Leth-Larsen R, et al. (2005) A common polymorphism in the SFTPD gene influences assembly, function, and concentration of surfactant protein D. J Immunol. 174(3): 1532-8.
- Moran AP, et al. (2005) Role of surfactant protein D (SP-D) in innate immunity in the gastric mucosa: evidence of interaction with Helicobacter pylori lipopolysaccharide. J Endotoxin Res. 11(6): 357-62.
- Hartl D, et al. (2006) Surfactant protein D in human lung diseases. Eur J Clin Invest. 36(6): 423-35.
- Krueger M, et al. (2006) Amino acid variants in Surfactant protein D are not associated with bronchial asthma. Pediatr Allergy Immunol. 17(1): 77-81.
- Glas J, et al. (2008) Increased plasma concentration of surfactant protein D in chronic periodontitis independent of SFTPD genotype: potential role as a biomarker. Tissue Antigens. 72(1): 21-8.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"